Literature DB >> 15980758

Azathioprine induced nodular regenerative hyperplasia in IBD patients.

Fady Daniel1, Jean-François Cadranel, Philippe Seksik, Alain Cazier, Jean-Paul Duong Van Huyen, Marianne Ziol, Pierre Coutarel, Patrick Loison, Raymond Jian, Philippe Marteau.   

Abstract

Purine analogues are major drugs in the treatment of inflammatory bowel diseases (IBD). We present four cases of nodular regenerative hyperplasia of the liver (NRH) developed in patients with IBD treated with azathioprine. All patients had either abnormal liver tests and/or low platelet count. Although biochemical and hematological abnormalities regressed after azathioprine withdrawal, the long term evolution of the hepatic lesions (and the risk to develop further complications including portal hypertension) remains to be determined. Male gender seems to be a major risk factor by providing a predisposing pharmacogenetic profile of purine analogue metabolism. Clinicians should be aware of this serious complication which may occur with any of the purine analogues (azathioprine, 6-mercaptopurine, and 6-thioguanine).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15980758     DOI: 10.1016/s0399-8320(05)82136-0

Source DB:  PubMed          Journal:  Gastroenterol Clin Biol        ISSN: 0399-8320


  10 in total

1.  Non-cirrhotic intrahepatic portal hypertension: associated gut diseases and prognostic factors.

Authors:  C E Eapen; Peter Nightingale; Stefan G Hubscher; Peter J Lane; Timothy Plant; Dimitris Velissaris; Elwyn Elias
Journal:  Dig Dis Sci       Date:  2010-05-25       Impact factor: 3.199

2.  Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine.

Authors:  G Vernier-Massouille; J Cosnes; M Lemann; P Marteau; W Reinisch; D Laharie; G Cadiot; Y Bouhnik; M De Vos; A Boureille; B Duclos; P Seksik; J-Y Mary; J-F Colombel
Journal:  Gut       Date:  2007-05-15       Impact factor: 23.059

Review 3.  Nodular regenerative hyperplasia: evolving concepts on underdiagnosed cause of portal hypertension.

Authors:  Marek Hartleb; Krzysztof Gutkowski; Piotr Milkiewicz
Journal:  World J Gastroenterol       Date:  2011-03-21       Impact factor: 5.742

Review 4.  Azathioprine-induced hepatitis and cholestasis occurring 1 year after treatment.

Authors:  Jason Chertoff; Sabikha Alam; Michael Black; Islam Y Elgendy
Journal:  BMJ Case Rep       Date:  2014-12-03

Review 5.  Use of allopurinol with low-dose 6-mercaptopurine in inflammatory bowel disease to achieve optimal active metabolite levels: a review of four cases and the literature.

Authors:  T N Witte; A L Ginsberg
Journal:  Can J Gastroenterol       Date:  2008-02       Impact factor: 3.522

6.  A systematic survey evaluating 6-thioguanine-related hepatotoxicity in patients with inflammatory bowel disease.

Authors:  Alexander Teml; Matthias Schwab; Daan W Hommes; Sven Almer; Milan Lukas; Thomas Feichtenschlager; Timothy Florin; Julia Seiderer; Wolfgang Petritsch; Bernd Bokemeyer; Wolfgang Kreisel; Klaus R Herrlinger; Peter Knoflach; Bruno Bonaz; Thomas Klugmann; Hans Herfarth; Nikolaus Pedarnig; Walter Reinisch
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

Review 7.  Thiopurines in inflammatory bowel disease revisited.

Authors:  Florian Bär; Christian Sina; Klaus Fellermann
Journal:  World J Gastroenterol       Date:  2013-03-21       Impact factor: 5.742

8.  Liver disorders in inflammatory bowel disease.

Authors:  Victor Uko; Suraj Thangada; Kadakkal Radhakrishnan
Journal:  Gastroenterol Res Pract       Date:  2012-02-15       Impact factor: 2.260

Review 9.  Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing.

Authors:  Alexander Teml; Elke Schaeffeler; Klaus R Herrlinger; Ulrich Klotz; Matthias Schwab
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 5.577

10.  Evaluation of azathioprine-induced cytotoxicity in an in vitro rat hepatocyte system.

Authors:  Abdullah Al Maruf; Luke Wan; Peter J O'Brien
Journal:  Biomed Res Int       Date:  2014-07-01       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.